Telix Pharmaceuticals (ASX:TLX) reported second-quarter revenue rose 21% to $247 million due to strong sale of precision medicine category, according to a Tuesday filing with the Australian bourse.

The company expects fiscal 2026 revenue and other income to be more than $1 billion, with income tracking in line with the upper end of outlook of $950 million to $970 million.

It increased its fiscal 2026 research and development expenditure outlook to $230 million to $270 million from prior range of $200 million to

$240 million.